@drtimos.bsky.socialWhat’s shaping CVC investments for 2025? Key trends: AI/ML, Gene Therapy, and a focus on Immune Disorders & Neurodegenerative Diseases. Curious for more? 📥 Download the full report for insights! http://dlvr.it/TVf4ht
#CVC #InvestingInInnovation #VentureCapital #GeneTherapy #AI
@genethonfr.bsky.social@genethonfr.bsky.social is registered to attend
@alliancerm.bsky.social
#CGMesa26!
Can't wait to dive into discussions, network with industry leaders, and explore the latest advancements in #cellandgenetherapy.
Let the countdown begin!
See you in Phoenix! 🌵🧬
@hastingscenter.bsky.social🧬 What can the death of Jesse Gelsinger teach us about research ethics today?
Join Hastings Center Fellow Arthur Caplan for an ELSIconversations webinar exploring the case’s lasting impact on #GeneTherapy and #ResearchEthics.
📅 Oct. 2 | 12 PM ET🔗 http://evt.to/gmaioguhw
@bio-integration.orgThis review explores vector innovations, curative targets, and delivery strategies, while addressing obstacles in clinical translation and prospects for treating #neurologic disorders. #medsky #Neurology #GeneTherapy
#BIOI #OpenAccess: doi.org/10.15212/bio...
@umasschan.bsky.socialThe FDA has approved a clinical trial for the ultra-rare disease Mucolipidosis Type IV that will take place at UMass Chan Medical School: https://direc.to/p3N5
Mass General Brigham researchers are co-leading the MLIV trial.
#ClinicalTrial #GeneTherapy #RareDisease @mgbresearch.bsky.social
@news.zovintus.comGroundbreaking CRISPR-Cas9 therapy successfully restores photoreceptor function in patients with inherited retinal degeneration, marking a monumental shift toward treating previously incurable genetic vision loss!
#CRISPR #GeneTherapy #Zovintus
[Image by AI]
@genehproject.bsky.socialExcellent science is not enough.
In our new #GeneH video, partners discuss what must change for #GeneTherapy research to
move closer to patients: regulation, manufacturing, funding, clinical pathways and stronger
collaboration.
�� Watch: youtu.be/KIc-uUvwjBs
#ResearchToPatients
@longevitytech.bsky.socialOut of 1,400 teams chasing the largest prize ever offered for reversing aging, an Austin gene therapy company made the final ten.
Link as first comment.
@drtimos.bsky.social🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TVcPqP #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT
@adityabasu.bsky.socialFDA clears UX111: The 1st systemic AAV9 gene therapy for pediatric Sanfilippo syndrome Type A (MPS IIIA)! Crossing the blood-brain barrier via IV infusion, it cuts CSF heparan sulfate >65% and stabilizes cognition.
Read full feature: url.nextechie.in/2nADch
@moltherapy.bsky.socialTODAY at 11 AM CDT: Molecular Therapy Presents - AI-Powered Precision Medicine: From Biomarker Discovery to Therapeutic Design and Delivery
Join us for this exciting FREE webinar today: http://dlvr.it/TVcMM4
#ArtificialIntelligence #GeneTherapy #RNAtherapeutics #ASGCT
@magic-horizon.bsky.socialMeet the people behind MAGIC 🎥
Dr Sinéad Ryan from Maynooth University works alongside Prof Karen English, exploring the immune challenges linked to gene therapies for muscular dystrophies. Their work is helping build a stronger foundation for safe and effective treatments.
@genethonfr.bsky.social📢 #WMS2026 Sept. 30
🎙️ Oral Session 3 (3:30–4:00 PM)
Mario Amendola: CRISPR-based utrophin upregulation for Duchenne muscular dystrophy
Vincent Laugel: Long-term Phase 1/2 results of GNT0004 gene therapy
📄 3 posters from @genethonfr.bsky.social
(5:15–6:15 PM)
@jmirlatestresearch.bsky.socialApplication of aiAtlas Version 1.2 to Simulate Variant Gene Function Restoration and Rescue Thresholds in Rare Diseases: Validation Case Study #ArtificialIntelligence #Genomics #RareDiseases #GeneTherapy #BiomedicalResearch
@dcrinews.bsky.socialThe DCRI is proud to be part of the Bespoke Gene Therapy Consortium, helping accelerate gene therapy research for rare diseases. Learn more: dcri.org/news/dcri-se...
#RareDiseaseResearch #GeneTherapy
@emg-gold.comBeacon Therapeutics’ gene therapy laru-zova has met its primary goal in a pivotal trial for X-linked retinitis pigmentosa, a rare eye disease with no approved treatments.
Read the full story: www.emjreviews.com/emj-gold/new...
@pharmaphorum.bsky.social#BeaconTherapeutics is preparing to file for approval of its #genetherapy for eye disorder #Xlinkedretinitispigmentosa (XLRP) after reporting positive results in a pivotal trial.
@coherebtmi792.bsky.socialCell Banking Outsourcing Market Trends, Size, and Growth Analysis 2026-2033
Read full blog on our website:
www.coherentmarketinsights.com/market-insig...
#CoherentMarketInsights #CellBankingOutsourcingMarket #Biopharmaceuticals #Biopharma #Biotechnology #GeneTherapy #CellTherapy
@prof-clark.bsky.socialCould functional vision be the future of retinal gene-therapy approvals? Beacon’s VISTA win in XLRP puts patient-relevant vision outcomes centre stage. #GeneTherapy #Ophthalmology buff.ly/MODKvwq
@thebabaklab.bsky.socialThe @fda.gov has approved the first gene therapy for children with Sanfilippo syndrome type A.
Link in the comments 👇
#ClinicalMondays #GeneTherapy #SanfilippoSyndrome #Pediatrics #OrphanDrug #FastTrack #BreakthroughTherapy
